December 14, 2016
J&J shareholding in Biocartis decreases
Johnson&Johnson has decreased its shareholding in Biocartis, the Belgian drugmaker said on Wednesday. In a disclosure of a transparency notification,…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
December 14, 2016
Genticel: two year trial of HPV16/18 immunotherapeutic candidate fails
Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), has…
December 13, 2016
GSK substitutes Pricewaterhouse with Delloite
GSK has announced on Tuesday that it intends to appoint Deloitte LLP (“Deloitte”) as its auditor with effect from the…
December 13, 2016
4D pharma’s Blautix for Irritable Bowel Syndrome shows positive impact
4D Pharma’s Blautix, a single strain live biotherapeutic for the treatment of chronic abdomen disorder, Irritable Bowel Syndrome (IBS), has…
December 13, 2016
Short: Active Biotech’s rights issue completed
Active Biotech has announced on Tuesday that following the end of the subscription period, the results of Active Biotech’s rights issue…
December 13, 2016
Zealand Pharma increases share capital
Zealand Pharma has on Monday increased its share capital with nominal DKK 13,999 divided into 13,999 new shares with a…
December 12, 2016
Novartis’s Monaleesa study show PFS in breast cancer treatment
Novartis has announced additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly prolonged progression-free…
December 12, 2016
Achaogen passes US and European hurdles to market its plazomicin antibiotic
Achaogen’s multi-drug resistant (MDR) gram-negative product antibiotic candidate, plazomicin, met the objective for the U.S. Food and Drug Administration (FDA)…
December 12, 2016
Ipsen science boss, R&D Vice President Claude Bertrand leaves
French drugmaker Ipsen said on Monday that Claude Bertrand, Executive Vice President, R&D, Chief Scientific Officer, will step down in January…
December 12, 2016
Short: Sycomore Asset Management’s share of Biocartis trigers transparency act
Biocartis Group NV said on Monday, in accordance with the Belgian Transparency Act, that Sycomore Asset Management now holds 3.01% of the…